Key result
Prior COVID-19 linked to ~129% higher in-stent restenosis odds and reduced one-year survival.
Why the study?
Inflammation plays a key role in in-stent restenosis, and the COVID-19 pandemic contributed to inflammation and coagulation activation, prompting assessment of restenosis risk factors and survival during the pandemic.
Does prior COVID-19 infection increase the risk of coronary artery restenosis and reduce survival in patients with coronary artery disease undergoing repeat myocardial revascularization?
Cross-Sectional (n=931)
Yes
Does prior COVID-19 infection increase the risk of coronary artery restenosis and reduce survival in patients with coronary artery disease undergoing repeat myocardial revascularization?
Prior COVID-19 infection is a significant risk factor for in-stent restenosis and is associated with reduced short- and long-term survival in patients undergoing repeat revascularization.
Answers are grounded in this paper and cite their sources.
May warrant closer restenosis surveillance in post-COVID patients; leaves open causality and requires prospective validation.
Background: In-stent restenosis of coronary arteries is a significant problem in interventional cardiology. Inflammatory processes in the arterial intima play a key role among the well-known risk factors for restenosis. The COVID-19 pandemic has contributed to the development of inflammation and the activation of the coagulation system. The aim of this study was to assess the risk factors for coronary artery restenosis and patient survival during the COVID-19 pandemic. Materials and Methods: We performed a cross-sectional study on a targeted sample of patients with coronary artery disease who underwent repeat myocardial revascularization (931 patients). The main study group, consisting of patients with coronary artery stent restenosis, included 420 patients (38.5% had previous COVID-19). The control group included 511 patients without stent restenosis (20.9% had COVID-19). Results: The results of multiple logistic regression analysis showed that the odds ratio (OR) for COVID-19 was 2.29 (95% CI 2.78–3.19) (p < 0.001), and the OR for C-reactive protein (CRP) was 1.08 (95% CI 1.002–1.013). The average hospital survival time for subjects with prior COVID-19 (N = 269) was 9.53 ± 0.106 days (95% CI 9.32–9.74), while for those without COVID-19 (N = 662), it was 9.89 ± 0.032 days (95% CI 9.83–9.96) (p < 0.001). The one-year survival time was 316.7 ± 6.982 days (95% CI 303.0–330.4) for the COVID-19 group and 340.14 ± 3.243 days (95% CI 333.8–346.5) for the non-COVID-19 group (p < 0.001). Conclusions: The main risk factors for in-stent restenosis were COVID-19 and elevated CRP levels. The average survival time in the group with prior COVID-19 was statistically significantly lower than in patients without COVID-19, both during the hospital stay and within one year after repeated revascularization.
No takes yet. Share an insight, caveat, or question.
Pivina et al. (2025) conducted a cross-sectional in Coronary artery disease requiring repeat myocardial revascularization (n=931). History of COVID-19 vs. No history of COVID-19 was evaluated on Coronary artery in-stent restenosis (OR 2.29, 95% CI 1.711-3.078, p=<0.001). Previous COVID-19 infection significantly increased the odds of coronary artery in-stent restenosis (OR 2.29) and reduced one-year survival in patients undergoing repeat myocardial revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: